190 related articles for article (PubMed ID: 28540417)
1. Monitoring early response to chemoradiotherapy with
Grkovski M; Lee NY; Schöder H; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1682-1691. PubMed ID: 28540417
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric Imaging of Tumor Hypoxia and Perfusion with
Grkovski M; Schöder H; Lee NY; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
J Nucl Med; 2017 Jul; 58(7):1072-1080. PubMed ID: 28183993
[TBL] [Abstract][Full Text] [Related]
3. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Analysis of Dynamic
Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
[TBL] [Abstract][Full Text] [Related]
5. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Optimal Post-Injection Timing of Hypoxic Imaging with
Kawamura M; Yoshimura M; Shimizu Y; Sano K; Ishimori T; Nakamoto Y; Mizowaki T; Hiraoka M
Mol Imaging Biol; 2021 Aug; 23(4):597-603. PubMed ID: 33475945
[TBL] [Abstract][Full Text] [Related]
7. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
8.
Grkovski M; Emmas SA; Carlin SD
J Nucl Med; 2017 Oct; 58(10):1567-1573. PubMed ID: 28360207
[TBL] [Abstract][Full Text] [Related]
9. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
[TBL] [Abstract][Full Text] [Related]
10. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
11. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times.
Grkovski M; Schwartz J; Gönen M; Schöder H; Lee NY; Carlin SD; Zanzonico PB; Humm JL; Nehmeh SA
J Nucl Med; 2016 Mar; 57(3):334-41. PubMed ID: 26609178
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of hypoxia (18)F-fluoromisonidazole dynamic PET in head and neck cancer.
Wang W; Lee NY; Georgi JC; Narayanan M; Guillem J; Schöder H; Humm JL
J Nucl Med; 2010 Jan; 51(1):37-45. PubMed ID: 20008982
[TBL] [Abstract][Full Text] [Related]
14. Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
Simoncic U; Leibfarth S; Welz S; Schwenzer N; Schmidt H; Reischl G; Pfannenberg C; Fougère C; Nikolaou K; Zips D; Thorwarth D
Med Phys; 2017 Jun; 44(6):2358-2368. PubMed ID: 28317128
[TBL] [Abstract][Full Text] [Related]
15. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic
Thorwarth D; Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D
J Nucl Med; 2019 Dec; 60(12):1698-1704. PubMed ID: 31076504
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
Jansen JF; Schöder H; Lee NY; Wang Y; Pfister DG; Fury MG; Stambuk HE; Humm JL; Koutcher JA; Shukla-Dave A
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1403-10. PubMed ID: 19906496
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
18. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
19. Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [
Kelada OJ; Rockwell S; Zheng MQ; Huang Y; Liu Y; Booth CJ; Decker RH; Oelfke U; Carson RE; Carlson DJ
Mol Imaging Biol; 2017 Dec; 19(6):893-902. PubMed ID: 28409339
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.
Thorwarth D; Eschmann SM; Scheiderbauer J; Paulsen F; Alber M
BMC Cancer; 2005 Dec; 5():152. PubMed ID: 16321146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
